Assess whether RWE can replace or only supplement an RCT (5a9c44)

Situation

A competitor label that just got a narrower indication put 505(b)(2) literature-to-product bridge table in front of labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT. This Pharma & Life Sciences / Clinical and Evidence Strategy close is RWE can replace or from 505(b)(2) literature-to-product bridge table, and the live options are RWE can replace, Only supplement an RCT.

Decision

Labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT must choose RWE can replace / Only supplement an RCT using 505(b)(2) literature-to-product bridge table after a competitor label that just got a narrower indication.

Hypotheses to test

• Authorize RWE can replace now; 505(b)(2) literature-to-product bridge table already has the discriminator after a competitor label that just got a narrower indication.
• Keep Only supplement an RCT in force until 505(b)(2) literature-to-product bridge table is completed after a competitor label that just got a narrower indication for labeling negotiator.
• Treat 505(b)(2) literature-to-product bridge table as RWE can replace because both readings appear after a competitor label that just got a narrower indication.
• Refuse a Pharma & Life Sciences close: labeling negotiator does not have the page RWE can replace or turns on in 505(b)(2) literature-to-product bridge table.

Analysis required

• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a competitor label that just got a narrower indication.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read 505(b)(2) literature-to-product bridge table against a competitor label that just got a narrower indication and write the one fact that would move RWE can replace or for labeling negotiator.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (505(b)(2) literature-to-product bridge table after a competitor label that just got a narrower indication). The follow-on Clinical and Evidence Strategy action is what labeling negotiator does next: implement the option, assign an owner, and log the missing fact.